Clearside Biomedical to Present at the 37th Annual J.P. Morgan Healthcare Conference
ALPHARETTA, Ga., Jan. 02, 2019 (GLOBE NEWSWIRE) — Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that […]
Qorvo® Module Enables Cellular Vehicle-to-Everything Trials by Major Automakers
Industry-leading front-end module is at the heart of Qualcomm’s C-V2X reference design GREENSBORO, N.C., Jan. 02, 2019 (GLOBE NEWSWIRE) — […]
NETSOL Technologies Appoints Industry Veteran Hui Liang as Company’s President of China
CALABASAS, Calif., Jan. 02, 2019 (GLOBE NEWSWIRE) — NETSOL Technologies, Inc. (NASDAQ: NTWK), a global business services and enterprise application […]
MyoKardia Regains Global Rights to Mavacamten and MYK-491 Programs from Sanofi
Management to Host Conference Call at 8:30 a.m. ET/5:30 a.m. PT SOUTH SAN FRANCISCO, Calif., Jan. 02, 2019 (GLOBE NEWSWIRE) […]
gammaCore™ Now Available Through U.S. Federal Government’s Federal Supply Schedule (FSS)
BASKING RIDGE, N.J., Jan. 02, 2019 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced […]
Daré Bioscience Provides Update for Investors on Development Programs and Anticipated 2019 Milestones
Key anticipated 2019 clinical milestones: Topline results of Ovaprene® PCT clinical trial Initiation of at-home portion of Sildenafil Cream, 3.6% […]
Genocea Doses First Patients and Completes Enrollment in Part A of Phase 1/2a Clinical Trial for Neoantigen Vaccine Candidate GEN-009
First immunogenicity data now expected in mid-2019 CAMBRIDGE, Mass., Jan. 02, 2019 (GLOBE NEWSWIRE) — Genocea Biosciences, Inc. (NASDAQ: GNCA), […]
Windstream President & CEO Tony Thomas to speak at Citi conference
LITTLE ROCK, Ark., Jan. 02, 2019 (GLOBE NEWSWIRE) — Tony Thomas, president and chief executive officer of Windstream, will speak […]
CymaBay Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference
NEWARK, Calif., Jan. 02, 2019 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing […]
Allena Pharmaceuticals Achieves Alignment with FDA on Phase 3 Program and Accelerated Approval Pathway for Reloxaliase in Enteric Hyperoxaluria
— Primary Efficacy Endpoint of Change in Urinary Oxalate Excretion at Four Weeks — — URIROX-2™, Second Pivotal Phase 3 […]
